Par Pharmaceutical Companies Q3 FY14: revenue $336.1M, up 26%

Key figures from this report

These are the numbers Par Pharmaceutical Companies reported for Q3 FY14, the quarter ended Sep 30, 2014, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$336.1M+26% from $267.3M in Q3 FY1310-Q income statement, on EDGAR
2. Net income−$37.6MAgainst −$29.3M in Q3 FY1310-Q income statement, on EDGAR
3. Cash and cash equivalents$108.7M+5% from $103.9M in Q3 FY13Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$37.7M−163% from $59.4M in Q3 FY1310-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters